证券之星消息，普洛药业(000739)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：看采访说公司26年一季度cdmo订单数量同比提升百分百，产能爆满，且26年公司很有信心利润创新高，是否属实？普洛药业回复：投资者您好！近年来，公司CDMO项目数持续保持较快增长，且逐渐进入商业化生产阶段，有助于CDMO产能利用率的回升；但公司CDMO项目与产能涉及多个子公司、众多生产线，部分产线的生产旺盛并不完全代表公司整体业务情况，也不构成对公司经营业绩的预期指引。请广大投资者以公司披露的公告为准，谨慎分析判断，注意投资风险。感谢您的关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.